AML Genomic Landscape Plays Key Role in Treatment
Pharmacy Times,
Jerry A. Barbee Jr, PharmD, BCPS, CPh; Glenn Schulman, PharmD, MS, BCPS, BCACP, BCGP, BCIDP; and Caitlin M.
Jerry A. Barbee Jr, PharmD, BCPS, CPh; Glenn Schulman, PharmD, MS, BCPS, BCACP, BCGP, BCIDP; and Caitlin M.
/PRNewswire/ -- Novartis today announced that full results from the Rydapt ® (midostaurin) Phase III RATIFY (CALGB 10603 [Allianc…
Significant overall survival benefit observed for FLT3+ AML patients consistent across FLT3 mutation subgroups, including ITD…